{"slideshow_credits": null, "snippet": "GlaxoSmithKline plans to take its bid for Human Genome Sciences directly to shareholders this week, after being rejected by the biotechnology company last month.", "abstract": "GlaxoSmithKline plans to take its bid for Human Genome Sciences directly to shareholders this week, after being rejected by the biotechnology company last month.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Dealbook", "role": "reported", "rank": 1, "organization": ""}], "original": "By DEALBOOK"}, "web_url": "http://dealbook.nytimes.com/2012/05/09/glaxosmithkline-to-make-hostile-bid-for-human-genome-sciences/", "lead_paragraph": null, "headline": {"main": "Glaxo to Make Hostile Bid for Human Genome Sciences", "kicker": "dealbook"}, "_id": "4fd3a41b8eb7c8105d8ee559", "word_count": "301", "multimedia": [], "pub_date": "2012-05-09T07:18:45Z", "source": "The New York Times", "news_desk": null, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "1"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}